ProfileGDS5678 / 1421377_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 9% 9% 9% 9% 10% 9% 9% 9% 9% 9% 9% 9% 10% 9% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.241869
GSM967853U87-EV human glioblastoma xenograft - Control 22.224399
GSM967854U87-EV human glioblastoma xenograft - Control 32.227569
GSM967855U87-EV human glioblastoma xenograft - Control 42.187339
GSM967856U87-EV human glioblastoma xenograft - Control 52.1963910
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.268179
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.228359
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.204289
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.199079
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.217519
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.215149
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.202479
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.2521810
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.215119